Clinical Trial to Assess New Pacing System in MRI Environment

MRI provides detailed images of organs and tissues without the use of radiation. Whereas these images can help clinicians make informed decisions about treatment and care, most pacemakers are not compatible with MRI technology and therefore patients may not have access to the sophisticated scanning capabilities of the diagnostic system.

The first patient in the United States has been implanted with the Boston Scientific Corp. (Natick, MA, USA) next-generation ImageReady MR Conditional pacing system in the Samurai clinical trial. The ImageReady pacing system is comprised of the Boston Scientific Ingenio MRI pacemaker product range and the new Ingevity MRI pacing leads. The proprietary technology is designed to reduce MRI interference with device performance. The Ingevity pacing lead platform, moreover, is designed to provide key enhancements in fixation and handling compared to standard leads currently available, and it is specifically engineered to function in the MRI environment.

“Physicians are very limited in device options and therapies labeled for use in the MRI setting,” said Ronald Berger, MD, PhD, professor of medicine, Johns Hopkins Medical Institutions. “The availability of a pacing system specifically designed to allow patients with pacemakers to undergo a broad set of MRI scanning conditions will advance the quality of patient care. The Ingenio MRI pacemaker family also offers pacing technologies not previously available in devices designed for the MRI environment.”

The ImageReady pacing system provides technologies exclusive to Boston Scientific, including RightRate rate adaptive pacing with the Minute Ventilation sensor, the only sensor clinically proven to restore chronotropic competence; Rythmiq, which is designed to minimize unnecessary RV pacing without clinically significant pauses; and Latitude NXT, which is geared towards minimizing clinic and patient burden with wireless remote follow-up.

“The ImageReady system is another example of our continued commitment to meaningful innovation,” said Kenneth Stein, MD, chief medical officer, cardiac rhythm management, Boston Scientific. “Our mission is to improve outcomes by providing patients and their physicians with access to the most advanced device therapies and diagnostic technologies.”

The Samurai trial is a prospective, open-label, two-group randomized, multicenter, global clinical study designed to support US Food and Drug Administration regulatory (FDA) approval. The trial is expected to enroll approximately 363 patients at 45 centers in seven countries. The first patient implant in the United States occurred at OhioHealth’s Riverside Methodist Hospital (Columbus, OH, USA) by Sreedhar Billakanty, MD Dr. Billakanty is the coinvestigator of the Samurai study at OhioHealth along with Gregory Kidwell, MD, system medical director of Electrophysiology Services. The first study implant worldwide occurred in Malaysia at the Institut Jantung Negara (Kuala Lumpur) by Razali Omar, MD.

The ImageReady pacing system is under clinical investigation and not currently available in the United States.

Related Links:
Boston Scientific